Clinical trialPhase 1 / Phase 2Completed
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 16 May 2016
- Expected end
- 14 April 2025
- Enrollment
- 229 participants
- Sites
- 16
- Primary outcomes
- Maximum Tolerated Dose(s)
- Sponsor
- Other
- Results posted
- No
- Last update
- 2 May 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.